US PTO rejects several Plavix claims in "non-final" action
This article was originally published in Scrip
Executive Summary
The US Patent and Trademark Office issued a "non-final" office action rejecting several claims covering Sanofi-Aventis/Bristol-Myers Squibb's Plavix (clopidogrel) in December, BMS has just revealed in an SEC regulatory filing.